Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression rates ...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of abstracts from its ...
Long-acting injections given once every two months can prevent HIV at least as well as daily pills for gay and bisexual men and transgender women, according to interim study results released May 18 by ...
Long-acting injectables (LAIs) are sustained drug delivery systems specifically designed so that medication is released into the body gradually over an extended period of time. Image Credit: Powder ...
First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says
British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus’s ...
The role of and indication for long-acting injectables is highlighted as a treatment approach for HIV. Adam C. Welch, PharmD, MBA: An evolving space is long-acting injectables. It sounds great: 1 ...
Clinic, waiting room Researchers assessed barriers associated with the implementation of long-acting injectable antiretroviral therapy at HIV clinics in the United States. Survey findings highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results